📊 RKDA Key Takeaways
Is Arcadia Biosciences, Inc. (RKDA) a Good Investment?
Arcadia Biosciences exhibits severe financial distress with deepening losses despite dramatic revenue growth. The company is burning $1.1M annually in operating cash flow against only $954K in cash reserves, providing less than one year of runway. Negative operating margins of -70.8% and net margins of -398.6% indicate the business model is fundamentally unprofitable and unsustainable without significant operational restructuring or capital infusion.
Explosive revenue growth comes off a very small base, while operating and net margins remain deeply negative and gross margin visibility is unclear. With only $0.26M in cash against -$4.74M operating cash outflow, the company likely requires near-term external financing, elevating dilution and going‑concern risk. Until it establishes durable gross margins and positive operating cash flow, fundamentals remain unfavorable.
Why Buy Arcadia Biosciences, Inc. Stock? RKDA Key Strengths
- Strong YoY revenue growth of 2098.2% demonstrates significant top-line acceleration
- Unlevered balance sheet with zero long-term debt reduces financial risk
- Healthy liquidity ratios (3.79x current ratio, 3.17x quick ratio) provide near-term operational flexibility
- Debt-free balance sheet (0.00x D/E, no long-term debt)
- Significant YoY revenue growth (+2098.2%)
- Current and quick ratios above 2x (3.09x/2.50x)
RKDA Stock Risks: Arcadia Biosciences, Inc. Investment Risks
- Critical cash runway of approximately 10 months at current -$1.1M annual operating cash burn rate
- Extreme unprofitability across all margins (operating -70.8%, net -398.6%) with no clear path to profitability
- Negative free cash flow of -$1.1M alongside minimal cash reserves of $954K creates existential liquidity risk
- Complete absence of insider buying activity (0 Form 4 filings in 90 days) signals lack of management confidence
- Negative ROE (-152%) and ROA (-82.4%) indicate severe losses relative to equity and asset base
- Severe liquidity risk: $259K cash vs -$4.74M OCF
- High dilution risk from likely capital raises
- Sustained losses with unclear gross margin (N/A)
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway until insolvency
- Path to gross profitability and operating break-even timeline
- Quarterly revenue sustainability and gross margin achievement
- Capital raise or debt financing activity to extend runway
- Gross margin (%)
- Operating cash flow (quarterly)
Arcadia Biosciences, Inc. (RKDA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.79x current ratio provides a solid financial cushion.
RKDA Profit Margin, ROE & Profitability Analysis
RKDA vs Energy Sector: How Arcadia Biosciences, Inc. Compares
How Arcadia Biosciences, Inc. compares to Energy sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Arcadia Biosciences, Inc. Stock Overvalued? RKDA Valuation Analysis 2026
Based on fundamental analysis, Arcadia Biosciences, Inc. has mixed fundamental signals relative to the Energy sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Arcadia Biosciences, Inc. Balance Sheet: RKDA Debt, Cash & Liquidity
RKDA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Arcadia Biosciences, Inc.'s revenue has declined by 37% over the 5-year period, indicating business contraction. The most recent EPS of $-5.17 indicates the company is currently unprofitable.
RKDA Revenue Growth, EPS Growth & YoY Performance
RKDA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.1M | $2.6M | $1.90 |
| Q3 2025 | $1.3M | $856.0K | $0.62 |
| Q2 2025 | $1.3M | $1.1M | $0.78 |
| Q1 2025 | $987.0K | -$2.4M | $-1.78 |
| Q3 2024 | $1.3M | -$1.6M | $-1.18 |
| Q2 2024 | $1.3M | $823.0K | $0.61 |
| Q1 2024 | $1.2M | -$2.4M | $-1.78 |
| Q3 2023 | $1.6M | -$2.6M | $-1.89 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Arcadia Biosciences, Inc. Dividends, Buybacks & Capital Allocation
RKDA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Arcadia Biosciences, Inc. (CIK: 0001469443)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RKDA
What is the AI rating for RKDA?
Arcadia Biosciences, Inc. (RKDA) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RKDA's key strengths?
Claude: Strong YoY revenue growth of 2098.2% demonstrates significant top-line acceleration. Unlevered balance sheet with zero long-term debt reduces financial risk. ChatGPT: Debt-free balance sheet (0.00x D/E, no long-term debt). Significant YoY revenue growth (+2098.2%).
What are the risks of investing in RKDA?
Claude: Critical cash runway of approximately 10 months at current -$1.1M annual operating cash burn rate. Extreme unprofitability across all margins (operating -70.8%, net -398.6%) with no clear path to profitability. ChatGPT: Severe liquidity risk: $259K cash vs -$4.74M OCF. High dilution risk from likely capital raises.
What is RKDA's revenue and growth?
Arcadia Biosciences, Inc. reported revenue of $1.1M.
Does RKDA pay dividends?
Arcadia Biosciences, Inc. does not currently pay dividends.
Where can I find RKDA SEC filings?
Official SEC filings for Arcadia Biosciences, Inc. (CIK: 0001469443) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RKDA's EPS?
Arcadia Biosciences, Inc. has a diluted EPS of $-2.11.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RKDA a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Arcadia Biosciences, Inc. has a STRONG SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RKDA stock overvalued or undervalued?
Valuation metrics for RKDA: ROE of -152.0% (sector avg: 14%), net margin of -398.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RKDA stock in 2026?
Our dual AI analysis gives Arcadia Biosciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RKDA's free cash flow?
Arcadia Biosciences, Inc.'s operating cash flow is $-1.1M, with capital expenditures of $0.0. FCF margin is -99.9%.
How does RKDA compare to other Energy stocks?
Vs Energy sector averages: Net margin -398.6% (avg: 12%), ROE -152.0% (avg: 14%), current ratio 3.79 (avg: 1.3).